Pharma Business review is using cookies

ContinueLearn More
Close
October 18, 2018

Diurnal puts hold on US development of adrenal drug Chronocort

Diurnal Group has decided to put a hold on all activities relating to the US development of its adrenal drug Chronocort following a failure in a recently concluded phase 3 trial in adults with congenital adrenal hyperplasia (CAH).

Continue
Image: Diurnal will suspend the US development of adrenal drug Chronocort. Photo: courtesy of jk1991 / FreeDigitalPhotos.net.
October 17, 2018

US firm Revolution Medicines buys Warp Drive Bio

Image: Revolution Medicines has acquired Warp Drive Bio. Photo: courtesy of rawpixel / Unsplash.
October 16, 2018

Roche’s Kadcyla reduces disease recurrence risk in breast cancer study

Image: Roche's location in Basel. Photo: courtesy of F. Hoffmann-La Roche Ltd

Contracts

October 8, 2018

hVIVO signs new contracts with global biopharmaceutical firm

Image: hVIVO has signed new contracts with global biopharmaceutical firm. Photo: courtesy of rawpixel / Unsplash.

Opiant signs contract with BARDA to accelerate OPTN003 product development

BioCryst bags contract to supply RAPIVAB antiviral flu therapy doses to CDC

Data science company IXICO extends contract with biopharmaceutical firm

Deals

Deals October 15, 2018

Dr. Reddy’s to sell API manufacturing business unit in Hyderabad, India

Pharmaceutical Business Review

Alliqua BioMedical, Adynxx enter into merger deal

Mundipharma buys Spanish biosimilars company Cinfa Biotech

Recipharm acquires Sanofi inhalation contract manufacturing business

Popular

  1. Silence Therapeutics launches interim European injunction application against Alnylam’s Onpattro
  2. Neurocrine Biosciences, Jnana Therapeutics to discover medicines for CNS disorders
  3. eTheRNA immunotherapies opens mRNA manufacturing facility in Belgium
  4. Roche gets FDA approval for Hemlibra for haemophilia A without factor VIII inhibitors
  5. Merck’s HIV therapy Delstrigo achieves primary efficacy endpoint in phase 3 study

Videos

Suppliers

Spotlight

Pharmaceutical Business Review
FDA and EMA accept Novartis’ filings for MS drug Siponimod
Pharmaceutical Business Review
Diurnal’s Chronocort fails in phase 3 congenital adrenal hyperplasia trial
Pharmaceutical Business Review
Bial and Eisai confirm effectiveness of epilepsy monotherapy Zebinix